Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 9/20 | 0.53 |
| ▸ | MAPT | P10636 | 13/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | FPR1 | P21462 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533345 | 0.91 | TP53 (0.51) | TP53MAPTRXFP1POLBLMNA | |
| SCHEMBL2405407 | 0.90 | MAPT (0.56) | TP53MAPTPOLBGAALMNA | |
| SCHEMBL2405313 | 0.87 | ESR2 (0.52) | TP53MAPTRXFP1FPR2POLB | |
| SCHEMBL2406353 | 0.86 | MAPT (0.56) | TP53MAPTRXFP1FPR1FPR2 | |
| SCHEMBL2403608 | 0.85 | TP53 (0.55) | TP53MAPTRXFP1FPR1FPR2 | |
| SCHEMBL2404836 | 0.85 | CHKA (0.57) | TP53MAPTRXFP1FPR1FPR2 | |
| SCHEMBL2403778 | 0.85 | MAPT (0.49) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL2403784 | 0.83 | RAB9A (0.54) | TP53MAPTRXFP1POLBSMN1; SMN2 | |
| SCHEMBL2403795 | 0.83 | MAPT (0.57) | TP53MAPTRXFP1POLBLMNA | |
| SCHEMBL2404323 | 0.83 | GAA (0.52) | TP53MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9381172-B2 | Small molecule choline kinase inhibitors, screening assays, and methods for treatment of neoplastic disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CLEM BRIAN | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257211-A1 | Small-Molecule Choline Kinase Inhibitors as Anti-Cancer Therapeutics | CHKA, CHKB, CEPT1 | TP53 1116/4885MAPT 1448/4885RXFP1 3392/4885 |
| US-20110212994-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders | CHKB, CHKA, CHAT | TP53 743/4885MAPT 1255/4885RXFP1 4256/4885 |
| US-20130012557-A1 | Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders | CHKB, CHKA, CHAT | TP53 707/4885MAPT 1122/4885RXFP1 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.